Danaher (DHR) Beats Q1 Earnings but Misses Revenue, Raises Full-Year Guidance

Recent Developments

Danaher Corporation (NYSE: DHR) reported first-quarter 2026 results on April 21, covering the period ended March 27, 2026. Sales reached $5.95 billion, up 3.7% year over year from $5.74 billion, according to the company. While the top line fell short of analyst expectations, non-GAAP earnings per share came in at $2.06, beating the consensus estimate by 6.4%.

Shares fell as much as 3.8% in premarket trading following the report before recovering. As of the latest session, the stock was trading near flat, according to Investing.com.

Despite the revenue miss, Danaher raised the upper end of its full-year earnings guidance, citing double-digit momentum in its Biotechnology and Life Sciences segments. The company published an earnings call slide deck alongside the results, providing additional detail on segment performance and the updated outlook.

Financial Snapshot

Danaher shares are currently trading at $195.50, up $0.75, or 0.39%, on the day. The previous close was $194.75. Over the past 52 weeks, the stock has traded between $180.03 and $242.80.

For Q1 2026, the company reported:

• Revenue of $5,951 million vs. $5,741 million in Q1 2025
• Non-GAAP EPS of $2.06, approximately 6.4% above consensus

The revenue result fell short of market expectations, but the earnings beat and raised guidance provided some support to the stock following its initial premarket decline.

Wall Street View

Analyst sentiment on Danaher remains broadly constructive. As of the April 1, 2026 consensus snapshot, the breakdown stands at 11 Strong Buy ratings, 15 Buy ratings, 4 Hold ratings, and 0 Sell or Strong Sell ratings. This distribution is unchanged from the prior period recorded on March 1, 2026, indicating no shift in analyst positioning around the earnings release. Price target data is not available at this time.

Key Takeaways

• Danaher reported Q1 2026 revenue of $5.95 billion, up 3.7% year over year but below analyst expectations.
• Non-GAAP EPS of $2.06 exceeded the consensus estimate by 6.4%.
• The company raised the upper end of its full-year earnings guidance, pointing to strength in Biotechnology and Life Sciences.
• Analyst consensus remains heavily weighted toward Buy, with 26 out of 30 covering analysts at Strong Buy or Buy as of April 1, 2026.